Indicators
Indicators
Value
Direction
MACD(12,26,9)
-2.166
Neutral
RSI(14)
51.219
Neutral
STOCH(KDJ)(9,3,3)
51.295
Neutral
ATR(14)
5.548
Low Volatility
CCI(14)
-59.731
Neutral
Williams %R
59.330
Sell
TRIX(12,20)
0.174
Sell
StochRSI(14)
50.021
Sell
IQVIA Holdings Inc
IQV221.454USD
-0.806-0.36%
Market hours （ET）Quotes delayed by 15 min
37.71BMarket Cap
30.19P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of IQVIA Holdings Inc
Currency: USD Updated: 2025-12-12Key Insights
IQVIA Holdings Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 7/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 249.55.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
IQVIA Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
25
analysts
Buy
Current Rating
249.550
Target Price
+11.62%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
IQVIA Holdings Inc Highlights
StrengthsRisks
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. It offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.
Industry Leader
The company's revenue leads the industry, with the latest annual revenue totaling USD 15.40B.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 15.40B.
Fairly Valued
The company’s latest PE is 30.30, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 175.98M shares, decreasing 0.47% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 2.79K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.10.
Financial Health
Currency: USD Updated: 2025-12-12The current financial score of IQVIA Holdings Inc is 8.74, ranking 37/404 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 4.10B, representing a year-over-year increase of 5.24%, while its net profit experienced a year-over-year increase of 16.14%.
Score
Financials
5.93
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.77
IQVIA Holdings Inc's Company Valuation
Currency: USD Updated: 2025-12-12The current valuation score of IQVIA Holdings Inc is 8.11, ranking 65/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is 30.30, which is 36.55% below the recent high of 41.38 and 38.96% above the recent low of 18.50.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 7/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-12The current earnings forecast score of IQVIA Holdings Inc is 8.40, ranking 129/404 in the Biotechnology & Medical Research industry. The average price target for IQVIA Holdings Inc is 254.00, with a high of 270.00 and a low of 200.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
25
analysts
Buy
Current Rating
249.550
Target Price
+11.62%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
IQVIA Holdings Inc
IQV
25
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
Ionis Pharmaceuticals Inc
IONS
24
Beigene Ltd
ONC
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-12The current price momentum score of IQVIA Holdings Inc is 7.14, ranking 178/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 233.07 and the support level at 212.68, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
222.558
Sell
MA10
224.490
Sell
MA20
224.015
Sell
MA50
216.483
Buy
MA100
202.203
Buy
MA200
181.297
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-12The current institutional shareholding score of IQVIA Holdings Inc is 10.00, ranking 1/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 103.33%, representing a quarter-over-quarter increase of 5.39%. The largest institutional shareholder is The Vanguard, holding a total of 19.41M shares, representing 11.40% of shares outstanding, with 0.21% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
GIC Private Limited
Geode Capital Management, L.L.C.
CPP Investments
AllianceBernstein L.P.
Boston Partners
Artisan Partners Limited Partnership
1
2
Risk Assessment
Currency: USD Updated: 2025-12-12The current risk assessment score of IQVIA Holdings Inc is 8.71, ranking 5/404 in the Biotechnology & Medical Research industry. The company's beta value is 1.37. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.37
VaR
+2.94%
240-Day Maximum Drawdown
+34.75%
240-Day Volatility
+37.80%
Return
Best Daily Return
60 days
+7.29%
120 days
+17.88%
5 years
+17.88%
Worst Daily Return
60 days
-2.79%
120 days
-3.71%
5 years
-8.79%
Sharpe Ratio
60 days
+2.59
120 days
+2.12
5 years
+0.27
Risk Assessment
Maximum Drawdown
240 days
+34.75%
3 years
+47.12%
5 years
+51.52%
Return-to-Drawdown Ratio
240 days
+0.33
3 years
-0.02
5 years
+0.07
Skewness
240 days
+1.52
3 years
+1.26
5 years
+0.92
Volatility
Realised Volatility
240 days
+37.80%
5 years
+31.72%
Standardised True Range
240 days
+2.59%
5 years
+2.58%
Downside Risk-Adjusted Return
120 days
+535.42%
240 days
+535.42%
Maximum Daily Upside Volatility
60 days
+23.61%
Maximum Daily Downside Volatility
60 days
+18.78%
Liquidity
Average Turnover Rate
60 days
+1.14%
120 days
+1.21%
5 years
--
Turnover Deviation
20 days
-10.23%
60 days
+39.93%
120 days
+48.64%
Peer Comparison
Biotechnology & Medical Research
IQVIA Holdings Inc
IQV
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.66 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of IQVIA Holdings Inc?
The TradingKey Stock Score provides a comprehensive assessment of IQVIA Holdings Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of IQVIA Holdings Inc’s performance and outlook.
How do we generate the financial health score of IQVIA Holdings Inc?
To generate the financial health score of IQVIA Holdings Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects IQVIA Holdings Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of IQVIA Holdings Inc.
How do we generate the company valuation score of IQVIA Holdings Inc?
To generate the company valuation score of IQVIA Holdings Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare IQVIA Holdings Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of IQVIA Holdings Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of IQVIA Holdings Inc.
How do we generate the earnings forecast score of IQVIA Holdings Inc?
To calculate the earnings forecast score of IQVIA Holdings Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on IQVIA Holdings Inc’s future.
How do we generate the price momentum score of IQVIA Holdings Inc?
When generating the price momentum score for IQVIA Holdings Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of IQVIA Holdings Inc’s prices. A higher score indicates a more stable short-term price trend for IQVIA Holdings Inc.
How do we generate the institutional confidence score of IQVIA Holdings Inc?
To generate the institutional confidence score of IQVIA Holdings Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about IQVIA Holdings Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of IQVIA Holdings Inc.
How do we generate the risk management score of IQVIA Holdings Inc?
To assess the risk management score of IQVIA Holdings Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of IQVIA Holdings Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of IQVIA Holdings Inc.
